

REMARKS

This paper is being filed in response to the Office Communication dated July 15, 2002 in which a restriction requirement has been issued.

The Examiner alleges that the following groups of claims each constitute a separately patentable invention:

Group I: Claims 1-11 related to a method of developing dendritic Langerhans type cells comprising culturing peripheral blood monocytes in a medium containing platelets; and

Group II: Claims 1-12 [sic, 12-13] related to a method of developing dendritic Langerhans type cells comprising culturing peripheral blood monocytes in a medium containing platelets while specifically omitting GM-CSF;

Applicants elect the invention of Group II for prosecution in this application, but for clarity have replaced claims 12-13 with new claims 14-27, which are fully supported by the application as filed.

Claims 1-11 (Group I) have been cancelled, but Applicants expressly reserve the right to prosecute the subject matter of Group I in a continuation, continuation-in-part, and/or divisional application.

Applicants do not believe any fee is due with this submission. Nevertheless, the
Commissioner is hereby authorized to deduct any fees required with this submission from
Deposit Account No. 02-4377. Two copies of this paper are enclosed.

Respectfully submitted,



Rochelle K. Seide
PTO Reg. No. 32,300

August 8, 2002

Attorney for Applicants
BAKER BOTTS L.L.P.
30 Rockefeller Plaza
New York, NY 10112
(212) 408-2500